Pyridine

Pyridine

SCHEMBL263683

SS.c1ccncc1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL27078281 1.00 TSHR (0.82)
Pyridine SCHEMBL29074488 0.96 TSHR (0.75)
Pyridine SCHEMBL28991498 0.96 TSHR (0.75)
Pyridine SCHEMBL28280231 0.92 NAPRT (0.69)
Pyridine SCHEMBL9037865 0.91 TSHR (1.00)
Benzene SCHEMBL10751789 0.91 TSHR (1.00)
SCHEMBL3052767 0.91 TSHR (1.00)
Pyridine SCHEMBL16 0.91
Benzene SCHEMBL1261317 0.91 TSHR (1.00)
SCHEMBL34466311 0.91 TSHR (1.00)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1639 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731186-A2 METHODS AND COMPOSITIONS FOR TREATING EPITHELIAL DISEASES The Regents of the University of California (US) 2026-04-29 EP claimed
EP-4717352-A1 A WHOLE-BLOOD COMPATIBLE MATRIX FOR EXTRACORPOREAL BLOOD TREATMENT Gambro Lundia AB (SE) 2026-04-01 EP claimed
EP-4717351-A1 A WHOLE-BLOOD COMPATIBLE DOUBLE-PEGYLATED MATRIX FOR EXTRACORPOREAL BLOOD TREATMENT Gambro Lundia AB (SE) 2026-04-01 EP claimed
US-12539349-B2 Biocompatible tissue-adhesive polymers TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2026-02-03 US claimed
EP-4673478-A2 ANTIBODIES TO HTRA1 AND CONJUGATES THEREOF Kodiak Sciences Inc. (US) 2026-01-07 EP claimed
EP-4626498-A1 BIODEGRADABLE SPLINT AND METHOD OF PRODUCING THE SAME Stryker European Operations Limited (IE) 2025-10-08 EP claimed
WO-2024263919-A2 METHODS AND COMPOSITIONS FOR TREATING EPITHELIAL DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-26 WO claimed
WO-2024182318-A2 ANTIBODIES TO HTRA1 AND CONJUGATES THEREOF KODIAK SCIENCES INC. (US) 2024-09-06 WO claimed
US-12036330-B2 Tissue substitute multilayer matrix and uses thereof NURAMI MEDICAL LTD. (IL) 2024-07-16 US claimed
EP-3954536-B1 A TISSUE SUBSTITUTE MULTILAYER MATRIX NURAMI MEDICAL LTD (IL) 2024-06-26 EP claimed
US-20040023852-A1 Hydroxypatite-targeting poly(ethylene glycol) and related polymers NEKTAR THERAPEUTICS 2004-02-05 US claimed
EP-1345982-A2 SYNTHESIS OF HIGH MOLECULAR WEIGHT NON-PEPTIDIC POLYMER DERIVATIVES Nektar Therapeutics Al, Corporation (US) 2003-09-24 EP claimed
EP-1337274-A2 HYDROXYAPATITE-TARGETING POLY(ETHYLENE GLYCOL) AND RELATED POLYMERS Shearwater Corporation (US) 2003-08-27 EP claimed
US-6436386-B1 FIRST TERMINUS IS A HYDROXYAPATITE-TARGETING MOIETY SUCH AS A BIPHOSPHONATE, SECOND TERMINUS IS CHEMICALLY REACTIVE WITH A BIOACTIVE AGENT IN A HYDROLYZABLE BOND SHEARWATER CORPORATION 2002-08-20 US claimed
WO-2002059179-A2 SYNTHESIS OF HIGH MOLECULAR WEIGHT NON-PEPTIDIC POLYMER DERIVATIVES SHEARWATER CORPORATION (US) 2002-08-01 WO claimed
US-20020082345-A1 Synthesis of high molecular weight non-peptidic polymer derivatives SHEARWATER CORPORATION 2002-06-27 US claimed
WO-2002040058-A2 HYDROXYAPATITE-TARGETING POLY(ETHYLENE GLYCOL) AND RELATED POLYMERS SHEARWATER CORPORATION (US) 2002-05-23 WO claimed
WO-2001010450-A1 TARGETED THROMBOLYTIC AGENTS IMARX THERAPEUTICS, INC. (US) 2001-02-15 WO claimed
US-5672662-A HYDROPHILIC POLYMERS SHEARWATER POLYMERS, INC. (US) 1997-09-30 US claimed
WO-1997003106-A1 POLY(ETHYLENE GLYCOL) AND RELATED POLYMERS MONOSUBSTITUTED WITH PROPIONIC OR BUTANOIC ACIDS AND FUNCTIONAL DERIVATIVES THEREOF FOR BIOTECHNICAL APPLICATIONS SHEARWATER POLYMERS, INC. (US) 1997-01-30 WO claimed